An unusual presentation of LCAT deficiency as nephrotic syndrome with normal serum HDL-C level

Manish R Balwani*, Vijaykumar A Ghodela, Vivek B Kute, Pankaj R Shah, Himanshu V Patel, Dinesh N Gera, Aruna Vanikar, Hargovind L Trivedi

1Department of Nephrology and Clinical Transplantation, Laboratory Medicine, Transfusion Services and Immunohematology, Institute of Kidney Diseases and Research Center, Dr. HL Trivedi Institute of Transplantation Sciences (IKDRC-ITS), Ahmedabad, India
2Department of Pathology, Laboratory Medicine, Transfusion Services and Immunohematology, Institute of Kidney Diseases and Research Center, Dr. HL Trivedi Institute of Transplantation Sciences, Ahmedabad, India

Introduction

Lecithin-cholesterol acyltransferase (LCAT) is a plasma enzyme that transesterifies cholesterol and phosphatidylcholines (lecithins) into cholesteryl esters and lysophosphatidylcholine (1). LCAT acts on both low-density lipoproteins (apolipoprotein [apo] B–containing lipoproteins like low-density lipoprotein [LDL]), very low-density lipoprotein [VLDL]) and high-density lipoproteins (HDLs), corresponding to the β- and α-activity of LCAT, respectively (2). LCAT binds to HDL particles preferentially which contain apoA-I, which is the main activator of enzyme, and is responsible for most of the cholesteryl ester synthesis (2,3). HDL promotes the efflux of excess cholesterol from peripheral tissues and for biliary excretion, returns it to the liver (4). Nascent HDL is secreted by liver and intestine as lipid-poor apoA-I and undergoes dynamic remodeling and intravascular maturation. LCAT plays a key role in this maturation process. The LCAT deficiency can be either acquired, usually secondary to liver disorder, or congenital with an autosomal recessive mode of inheritance. Mutations in the LCAT gene result in either milder phenotype known as fish-eye disease or severe familial LCAT deficiency (5). Mutated LCAT genotype results in a gene-dose–dependent alteration in plasma lipid/lipoprotein profile, hematologic abnormalities and renal disease with or without premature cardiovascular disease (6-8). Patients with familial LCAT deficiency have complete loss of LCAT activity with an increased proportion of unesterified cholesterol in plasma with markedly reduced HDL-C. Clinical features include renal disease with proteinuria, with progression to end-stage renal disease (ESRD), corneal opacification and anemia (5). In fish-eye disease, there is a partial loss of LCAT enzyme activity, a selective loss of HDL associated α-LCAT activity and preserved activity toward apolipoprotein B-containing lipoprotein.

ARTICLE INFO

Article Type: Case Report

Article History:
Received: 12 December 2015
Accepted: 3 January 2016
ePublished: 5 January 2016

Keywords:
LCAT deficiency
Nephrotic syndrome
Corneal deposit
Anemia

ABSTRACT

Clinical and biochemical manifestations of lecithin-cholesterol acyltransferase (LCAT) deficiency include an abnormal lipid profile (characterized by hypercholesterolemia with markedly decreased high-density lipoprotein cholesterol [HDL-C] and hypertriglyceridemia), corneal opacities, hematologic abnormalities (normochromic anemia of varying intensity), splenomegaly, variable early coronary artery disease and nephropathy (initially proteinuria followed by progressive deterioration of renal function). We presented a patient with nephrotic syndrome, which renal biopsy revealed classic features of LCAT deficiency. To our knowledge, the present case is the first reported case of LCAT deficiency presenting with symptoms related to nephrotic syndrome in a patient with no obvious family history without any corneal deposits and normal HDL-C levels.

Implication for health policy/practice/research/medical education:
Lecithin-cholesterol acyltransferase (LCAT) deficient patients may present with renal disease only even with normal high-density lipoprotein cholesterol (HDL-C) levels. Hence, it needs high index of suspicion for LCAT deficiency when renal biopsy is suggestive of lamellar foamy deposits in mesangium and capillary walls even if serum HDL-C levels are normal.

Please cite this paper as: Balwani MR, Ghodela VA, Kute VB, Shah PR, Patel HV, Gera DN, et al. An unusual presentation of LCAT deficiency as nephrotic syndrome with normal serum HDL-C level. J Nephropharmacol. 2017;6(1):23-26.

*Corresponding author: Manish R Balwani, Email: balwani.manish@yahoo.com
It causes normal to slightly elevated free cholesterol in plasma with marked reduction in HDL cholesterol and corneal opacification without renal disease (9,10). Premature coronary artery disease is not seen in most familial LCAT deficiency cases but may be present in few of patients with familial LCAT deficiency (8). Patients with LCAT deficiency show inhomogeneous tissue and plasma lipoprotein abnormalities (11). Lesions are found in commonly affected tissues like kidney, spleen, cornea, and erythrocytes, probably due to lipid abnormalities (12,13). Kidney disease is a major cause of morbidity and mortality, where ESRD is a common outcome (14,15). Ultrastructural analysis of kidney shows expansion of mesangium and peripheral basement membranes with irregular vacuoles containing highly osmiophilic “lamellar bodies” (16). Altered phospholipid composition of erythrocytes may lead to mild anemia due to phagocytosis (17). We report a patient who presented with symptoms related to nephrotic syndrome and had an abnormal lipid profile with normal HDL-C and without corneal deposits who was finally diagnosed with LCAT deficiency. This case describes the spectrum of biochemical and renal manifestations of LCAT deficiency with associated histologic and ultrastructural findings.

Case Presentation
A 28-year-old female was admitted to our hospital with history of gradually progressive pedal edema and weight gain of 4 kg since 4 months. There was no other complaint on presentation. The family history was insignificant. On physical examination, she had normal vitals along with normal systemic examination except bilateral pitting pedal edema. Ophthalmic examination including fundoscopy was unremarkable. Laboratory data on admission showed hemoglobin: 9.3 g/dl, mean corpuscular volume (MCV); 82.6 fl, white blood count (WBC); 9690/µl with a normal differential count. Additionally poikilocytosis and ‘target’ erythrocytes in peripheral blood smear were seen. Around 3.3 g/day proteinuria was also found, while hematuria was not existed. Serum blood urea nitrogen and creatinine were 24 mg/dl and 0.99 mg/dl respectively. Serum total proteins were 4.5 g/dl (serum albumin 2.5 g/dl). Liver function tests and lactate dehydrogenase levels, prothrombin time, and partial thromboplastin time were within normal limits. She had a raised total serum cholesterol (415 mg/dl) and triglycerides (402 mg/dl) levels. There was also high serum VLDL (80.40 mg/dl) and normal HDL-C (63 mg/dl). Coombs test and autoantibodies was negative. Serum complements consisting C3 and C4, was within the normal range. A renal biopsy was conducted to find the etiology of nephrotic syndrome. Light microscopy showed 22 glomeruli with variable affection and enlarged size (Figure 1). Normal glomerular architecture was replaced by markedly dilated capillary lumina, which was filled with a lamellated, pink staining, fluid-like material. Mesangial matrix was focally increased and showed bubbly appearance. Capillary membranes showed craters on silver staining. Tubules showed moderate degeneration. Electron microscopy examination showed lipid deposition in the lamina densa of the basement membranes. The cystically dilated capillary loops revealed concentrically lamellated/myelinoid structures. Glomeruli were enlarged due to marked accumulation of amorphous lipid material in the capillary loops. Immunofluorescence examination of renal biopsy specimen was not done due to inadequate sample size. Finally, the evaluation of the plasma LCAT enzymatic activity revealed markedly decreased LCAT activity (10.1 nmol/ml/h; reference range, 80.9±11.2 nmol/ml/h). We confirmed again the absence of corneal opacities or any kind of ophthalmic involvement. The patient was treated with a combination of gemfibrozil, atorvastatin, and telmisartan without any significant improvement in proteinuria at 2 months of follow-up.

Discussion
Familial LCAT deficiency was initially described in people of northern European origin and subsequently in patients from different geographic areas, including Japan and North America (7,8,18,19). Variable clinical and biochemical manifestations of LCAT deficiency include an abnormal lipid profile (characterized by hypercholesterolemia with markedly decreased HDL-C and hypertriglyceridemia), corneal opacities, hematologic abnormalities (normochromic anemia of varying intensity), splenomegaly, variable early coronary artery disease and nephropathy (initially proteinuria followed by progressive deterioration of renal function) (8,17,20). In the current case, we made a working diagnosis of
nephrotic syndrome with secondary hyperlipidemia. The diagnosis of LCAT deficiency was made by retrospective evaluation after renal biopsy findings which were typical of LCAT deficiency. She was subsequently found to have an abnormal lipid profile characterized by high total cholesterol, high triglycerides, low to normal HDL-C, and low esterified cholesterol. The low HDL-cholesterol level is thought to be responsible for the less efficient reverse cholesterol transport and so accumulation of cholesterol in tissue (21). Along with removal of cholesterol from peripheral tissue, HDL-C also removes oxidized lipids from peripheral tissue (22). Consequently, oxidized lipids and lipid aggregates cause the activation of macrophages and thus promoting foamy histiocytes formation (23). Mild anemia with target cells was seen in our patient. Anemia is probably due to slight hemolysis in conjunction with insufficient erythropoiesis (18). The erythrocytes of patients with LCAT deficiency have structural and functional abnormalities, like decreased osmotic fragility and altered phospholipid composition (24). These abnormalities in lipid composition may lead to phagocytosis and thus mild anemia (17). Renal disease is a major cause of morbidity and mortality in patients with LCAT deficiency. Nephrotic syndrome frequently progresses to ESRD necessitating dialysis and kidney transplantation (14,15). Our patient was found to have the typical early renal manifestations and corresponding pathologic findings that are related to the abnormal lipid metabolism in patients with LCAT deficiency. Abnormal storage of lipids in kidney may occur in a number of disorders either due to an inborn error of metabolism or as a consequence of metabolic alteration such as in nephrotic syndrome (25). The characteristic light microscopic findings (i.e., mesangial expansion, capillary wall thickening, and vacuolation) and the ultrastructural appearance (lipid deposits in many areas including subendothelium and mesangium, and also lamellar structures) of the kidney specimen from our patient are typical findings in LCAT deficiency (25). Clinical features of patients with LCAT deficiency may vary even among the members of the same family (26). We have treated our patient with lipid lowering agents and angiotensin converting enzyme inhibitors, however, there has been no improvement after two months of follow-up. There is no specific treatment established yet for familial LCAT deficiency. Transplantation of the cornea or kidney was performed in cases with severe disease, although the disease has been reported to recur in the transplanted kidney (27). To our knowledge, the present case is the first reported case of LCAT deficiency presenting with symptoms related to nephrotic syndrome in a patient with no obvious family history without any corneal deposits and normal HDL-C levels. We could not find the reason for normal HDL-C in this patient. This case describes a spectrum of biochemical and renal manifestations of LCAT deficiency with histological and ultrastructural correlation. LCAT deficient patients may present with renal disease even with normal HDL-C levels. Hence, it needs high index of suspicion for LCAT deficiency when renal biopsy is suggestive of lamellar foamy deposits in the capillary lumina, mesangium and capillary walls, even if serum HDL-C levels are normal.

Conclusion
LCAT deficiency usually presents as renal disease with proteinuria, ESRD, corneal opacification, hypertriglyceridemia, low HDLC levels and anemia. In our case, LCAT deficient patient presented with nephrotic syndrome with no evidence of corneal deposits and with normal HDL-C levels.

Authors' contribution
All authors wrote the paper equally.

Conflicts of interest
The authors declared no competing interests.

Ethical considerations
Ethical issues (including plagiarism, data fabrication, double publication) have been completely observed by authors.

Funding/Support
None.

References
1. Jonas A. Lecithin cholesterol acyltransferase. Biochim Biophys Acta. 2000;1529:245-56.
2. Jonas A. Lecithin-cholesterol acyltransferase in the metabolism of high-density lipoproteins. Biochim Biophys Acta. 1991;1084:205-20.
3. Glomset JA. The plasma lecithins: cholesterol acyltransferase reaction. J Lipid Res. 1968;9:155-67.
4. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res 2005;96:1221-32.
5. Kuivenhoven JA, Pritchard H, Hill J, Frohlich J, Assmann G, Kastelein J. The molecular pathology of lecithin:cholesterol acyltransferase (LCAT) deficiency syndromes. J Lipid Res 1997;38:191-205.
6. Faiivre L, Saugier-Weber P, Pais de Barros JP, Verges B, Courret B, Lorcerie B, et al. Variable expressivity of the clinical and biochemical phenotype associated with the apolipoprotein E p.Leu149del mutation. Eur J Hum Genet. 2005;13:1186-91.
7. Calabresi L, Pisciotta L, Costantin A, Frigerio I, Eberini I, Alessandrini P, et al. The molecular basis of lecithin:cholesterol acyltransferase deficiency syndromes: a comprehensive study of molecular and biochemical findings in 13 unrelated Italian families. Arterioscler Thromb Vasc Biol. 2005;25:1972-8.
8. Ayyobi AF, McGladdery SH, Chan S, John Mancini GB, Hill JS, Frohlich JJ. Lecithin: cholesterol acyltransferase (LCAT) deficiency and risk of vascular disease: 25 year follow-up. Atherosclerosis. 2004;177:361-6.
9. Carlson LA, Philipson B. Fish-eye disease. A new familial condition with massive corneal opacities and dyslipoproteinaemia. Lancet. 1979;2:922-4.
10. Klein HG, Santamarina-Fojo S, Duverger N, Clerc M, Dumon MF, Albers JJ, et al. Fish eye syndrome: a molecular defect in the lecithin cholesterol acyltransferase (LCAT) gene associated with normal alpha- LCAT–specific activity. Implications for classification and prognosis. J Clin Invest. 1993;92:479-85.
11. Schmitz G, Muller G. Structure and function of lamellar bodies, lipid protein complexes involved in storage and secretion of cellular lipids. J Lipid Res. 1991;32:1539-70.
12. Stokke KT, Bjerve KS, Blomhoff JP, Oystese B, Flatmark A, Norum KR, et al. Familial lecithin:cholesterol acyltransferase deficiency. Studies on lipid composition and morphology of tissues. Scand J Clin Lab Invest Suppl. 1974;137:93-100.
13. Hovig T, Gjone E. Familial plasma lecithin: cholesterol acyltransferase (LCAT) deficiency. Ultrastructural aspects of a new syndrome with particular reference to lesions in the kidneys and the spleen. Acta Pathol Microbiol Scand. 1973;81:681-97.
14. Silverstein MN, Ellefson RD. The syndrome of the sea-blue histiocyte. Semin Hematol. 1972;9:293-307.
15. Weber CL, Frohlich J, Wang J, Hegele RA, Chan-Yan C. Stability of lipids on peritoneal dialysis in a patient with familial LCAT deficiency. Nephrol Dial Transplant. 2007;22:2084-8.
16. Imbasciati E, Paties C, Scarpioni L, Mihatsch MJ. Renal lesions in familial lecithin-cholesterol acyltransferase deficiency. Ultrastructural heterogeneity of glomerular changes. Am J Nephrol 1986;6:66-70.
17. Jacobsen CD, Gjone E, Hovig T. Sea-blue histiocytes in familial lecithin: cholesterol acyltransferase deficiency. Scand J Haematol. 1972;9:106-13.
18. Gjone E, Norum KR. Familial serum cholesterol ester deficiency. Clinical study of a patient with a new syndrome. Acta Med Scand. 1968;183:107-12.
19. Murayama N, Asano Y, Kato K, Sakamoto Y, Hosoda S, Yamada N, et al. Effects of plasma infusion on plasma lipids, apoproteins and plasma enzyme activities in familial lecithin: cholesterol acyltransferase deficiency. Eur J Clin Invest. 1984;14:122-9.
20. Shojaian AM, Jain SK, Shoht SB. Hereditary lecithin-cholesterol acyltransferase deficiency. Report of 2 new cases and review of the literature. Clin Invest Med. 1983;6:49-55.
21. Shah PK, Kaul S, Nilsson J, Cercek B. Exploiting the vascular protective effects of high density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part II. Circulation. 2001;104:2498-502.
22. Badimon JJ, Fuster V, Badimon L. Role of high density lipoproteins in the regression of atherosclerosis. Circulation. 1992;86:III86-94.
23. Steinberg D. Low density lipoprotein oxidation and its pathological significance. J Biol Chem. 1997;272:20963-6.
24. Godin DV, Gray GR, Frohlich J. Erythrocyte membrane alterations in lecithin: cholesterol acyltransferase deficiency. Scand J Clin Lab Invest Suppl. 1978;150:162-7.
25. Faraggiana T, Chung J. Renal lipidoses: a review. Hum Pathol. 1987;18:661-79.
26. Funke H, von Eckardstein A, Pritchard PH, Hornby AE, Wiebusch H, Motz C, etal. Genetic and phenotypic heterogeneity in familial lecithin:cholesterol acyltransferase (LCAT) deficiency. Six newly identified defective alleles further contribute to the structural heterogeneity in this disease. J Clin Invest. 1993;91:677-83.
27. Panescu V, Grignon Y, Hestin D, Rostoker G, Frimat L, Renoult E, et al. Recurrence of lecithin cholesterol acyltransferase deficiency after kidney transplantation. Nephrol Dial Transplant. 1997;12:2430-2.